| Title |
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2014
|
| DOI | 10.1007/s00280-014-2547-0 |
| Pubmed ID | |
| Authors |
Andrés Poveda, Xavier García del Muro, Jose Antonio López-Guerrero, Virginia Martínez, Ignacio Romero, Claudia Valverde, Ricardo Cubedo, Javier Martín-Broto |
| Abstract |
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95 %) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor α-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 40 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 7 | 17% |
| Student > Bachelor | 5 | 12% |
| Other | 5 | 12% |
| Researcher | 5 | 12% |
| Student > Doctoral Student | 4 | 10% |
| Other | 10 | 24% |
| Unknown | 5 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 59% |
| Social Sciences | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 5 | 12% |
| Unknown | 6 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2017.
All research outputs
#6,032,216
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#551
of 2,501 outputs
Outputs of similar age
#57,355
of 240,402 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#8
of 32 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,402 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.